MitoMYcin (Systemic)

Name: MitoMYcin (Systemic)

Uses of MitoMYcin

  • It is used to treat stomach cancer.
  • It is used to treat pancreatic cancer.
  • It may be given to you for other reasons. Talk with the doctor.
  • If you have been given mitoMYcin (systemic) for some other reason, talk with your doctor about the benefits and risks. Talk with your doctor if you have questions or concerns about using this medicine.

If OVERDOSE is suspected

If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.


(mye toe MYE sin)

Pharmacologic Category

  • Antineoplastic Agent, Antibiotic

Use Labeled Indications

Gastric cancer: Treatment of disseminated adenocarcinoma of the stomach (in combination with other chemotherapy agents) and as palliative treatment when other modalities have failed.

Pancreatic cancer: Treatment of disseminated adenocarcinoma of the pancreas (in combination with other chemotherapy agents) and as palliative treatment when other modalities have failed.

Limitations of use: Not recommended for single-agent primary therapy or to replace appropriate surgery and/or radiotherapy in the treatment of these conditions.


IV: Administer by slow IV push/bolus via a freely-running saline infusion. Consider using a central venous catheter.

Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.

Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity. Initiate dimethyl sulfate (DMSO) antidote. Apply dry cold compress for 20 minutes 4 times/day for 1 to 2 days (Pérez Fidalgo 2012).

DMSO: Apply topically to a region covering twice the affected area every 8 hours for 7 days; begin within 10 minutes of extravasation; do not cover with a dressing (Perez Fidalgo 2012).

Intravesicular (off-label route): Instill into bladder and retain for 1 to 2 hours (Au 2001; Friedrich 2007; Hall 2007; O’Brien 2013); rotate patient every 15 to 30 minutes


Store intact vials at 25°C (77°F); avoid exposure to temperatures >40°C (104°F). Reconstituted solution is stable for 7 days at room temperature and 14 days when refrigerated. Protect reconstituted solution from light. Solutions further diluted for infusion (concentration 20 to 40 mcg/mL) are stable for 12 hours at room temperature when diluted in NS and 24 hours at room temperature when diluted in sodium lactate.

Monitoring Parameters

Monitor CBC with differential (repeatedly during therapy and for ≥8 weeks following therapy); serum creatinine; pulmonary function tests; monitor for signs/symptoms of HUS; monitor infusion site.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience nausea, vomiting, mouth irritation, lip irritation, hair loss, or lack of appetite. Have patient report immediately to prescriber signs of infection, signs of bleeding (vomiting blood or vomit that looks like coffee grounds; coughing up blood; hematuria; black, red, or tarry stools; bleeding from the gums; abnormal vaginal bleeding; bruises without a reason or that get bigger; or any severe or persistent bleeding), signs of hemolytic-uremic syndrome (urinary retention; loss of strength and energy; signs of bleeding or bruising; fever; or swelling of the face, hands, feet, or body), signs of kidney problems (urinary retention, hematuria, change in amount of urine passed, or weight gain), severe dizziness, passing out, jaundice, pale skin, severe loss of strength and energy, shortness of breath, cough, excessive weight gain, swelling of arms or legs, or severe injection site redness, pain, edema, or irritation (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.